Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Bacteria are key contributors to the cause of IBS, study confirms

An overgrowth of bacteria in the gut has been definitively linked to Irritable Bowel Syndrome in the results of a new Cedars-Sinai study which used cultures from the small intestine. This is the first study to use this "gold standard" method of connecting bacteria to the cause of the disease that affects an estimated 30 million people in the United States.

25 May 2012

New research reveals effective treatments for gastrointestinal conditions

New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.

22 May 2012

AltheRx reports positive Phase II results of Solabegron for OAB

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the American Urological Association Annual Meeting (Abstract # 520).

21 May 2012

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos Corporation announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

18 May 2012

Latest science reveals Australians need to swallow some grains of truth about staple foods

A new report has revealed that the simplification of complex nutritional messages has resulted in grain foods like bread and pasta becoming the ‘scapegoat’ for weight gain and bloating, despite ample research to the contrary.

9 May 2012

Salix first quarter total product revenue increases 62% to $171.1M

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

8 May 2012

Specific proteins can help identify patients with IBS

Irritable bowel syndrome (IBS) is hard to diagnose as well as treat, but researchers at the Sahlgrenska Academy, at the University of Gothenburg, Sweden, have discovered a way of confirming the disorder using stool samples.

8 May 2012

Lexicon to receive funding for LX4211 Phase 2 trial in type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that an independent, non-profit organization will provide funding to support the Phase 2 development of LX4211 in type 1 diabetes.

4 May 2012

Lexicon first quarter revenues decrease 50% to $0.3 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2012.

3 May 2012

Study reveals direct correlation between negative thinking about pain and poor sleep

Chronic pain sufferers who learn to dwell less on their ailments may sleep better and experience less day-to-day pain, according to results of research conducted on 214 people with chronic face and jaw pain.

27 Apr 2012

Change in attitude may ease chronic pain by aiding sleep: Study

26 Apr 2012

FDA extends review period for linaclotide NDA to treat constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) notified the companies that it will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC).

23 Apr 2012

Women with IBS more likely to suffer from ectopic pregnancies, miscarriages

A study by researchers at University College Cork, Ireland and the University of Manchester, UK suggests that women with Irritable Bowel Syndrome are more likely to suffer from miscarriages and ectopic pregnancies.

4 Apr 2012

Hypnotherapy effective for treating bowel disorder IBS

Hypnosis can be a highly effective treatment for the bowel disorder IBS. Studies involving a total of 346 patients conducted by researchers at The Sahlgrenska Academy of the University of Gothenburg, Sweden, showed that hypnotherapy alleviated symptoms in 40 per cent of those affected - and that the improvement is long-term.

2 Apr 2012

Patients with IBD, other GI disorders may be exposed to higher levels of diagnostic radiation

Patients with inflammatory bowel disease (IBD) and other gastrointestinal (GI) disorders may be exposed to significant doses of diagnostic radiation, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

30 Mar 2012

Patients with IBS have higher prevalence of early adverse life events

Patients with irritable bowel syndrome (IBS) have a significantly greater prevalence of early adverse life events , including general trauma as well as physical, emotional and sexual abuse, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

30 Mar 2012

Rifaximin and lubiprostone offer best options for patients with IBS

Cedars-Sinai researchers have determined that two prevalent drug therapies - rifaximin and lubiprostone - offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects up to one in five Americans.

26 Mar 2012

GUCY2C gene mutation leads to familial diarrhea syndrome

When the intestines are not able to properly process our diet, a variety of disorders can develop, with chronic diarrhea as a common symptom. Chronic diarrhea can also be inherited, most commonly through conditions with genetic components such as irritable bowel syndrome. Researchers in Norway, India, and at the HudsonAlpha Institute for Biotechnology have identified one heritable DNA mutation that leads to chronic diarrhea and bowel inflammation.

22 Mar 2012

Lexicon receives FDA Orphan Drug designation for telotristat etiprate to treat carcinoid syndrome

Lexicon Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted its request for Orphan Drug designation for telotristat etiprate (LX1032) for the treatment of carcinoid syndrome.

21 Mar 2012

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that the first patient was dosed in a phase 2 clinical trial in the US for patients suffering with chronic constipation using their new chemical entity YKP10811.

17 Mar 2012